meta
|
evidence
oncology
Living systematic review and meta-analysis
metastatic-recurrent HNSCC (mHNSCC)
mHNSCC - (neo)adjuvant (NA)
mHNSCC - 1st line (L1)
mHNSCC - L1 - all population
2
mHNSCC - L1 - PDL1 positive
4
mHNSCC - 2nd line (L2)
mHNSCC - L2 - all population
4
mHNSCC - L2 - PDL1 negative
2
mHNSCC - L2 - PDL1 positive
1
hepatocell cancer (HCC)
immune chekpoint inhibitors
anti-PD-(L)1
atezolizumab based treatment
atezolizumab alone
durvalumab based treatment
durvalumab alone
nivolumab based treatment
nivolumab alone
nivolumab plus epacadostat
pembrolizumab based treatment
pembrolizumab alone
pembrolizumab plus 5FU plus platin
retifanlimab plus enoblituzumab
Immune checkpoint association
durvalumab plus tremelimumab
nivolumab plus ipilimumab
no study with result for this clinical condition